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Purpose: To evaluate the surgical learning curve in episceral plaque brachytherapy placement 
in the management of posterior uveal melanoma.
Methods: A retrospective chart review of two cohorts of 250 consecutive patients   undergoing 
plaque placement for posterior uveal melanoma from 2002 to 2004 and from 2008 to 2009 
was conducted. The plaque–tumor apposition rates verified by intraoperative echography were 
evaluated and correlated with surgical volume over a 19-year period.
Results: In an initial study of 29 consecutive patients undergoing plaque placement from 
  January 1992 to January 1995, a suboptimal plaque placement rate of 21% (n = 29) was identi-
fied. This percentage declined to 12% (n = 100) from January 2002 to January 2004, and further 
declined to 4% (n = 150) from June 2008 to August 2009. The tumor–plaque apposition rates 
for these three groups were 79% (1992–1995), 88% (2002–2004), and 96% (2008–2009). An 
estimated surgical volume of 1275 cases was performed to achieve a .90% precision rate for 
first application of primary plaque centration.
Conclusion: There are challenges to mastering the precise placement of radioactive plaques 
for posterior uveal melanoma. We have demonstrated a significant learning curve for plaque 
placement techniques, and have emphasized the importance of intraoperative ultrasound in the 
verification of plaque placement, thus allowing for intraoperative repositioning.
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Introduction
Surgical proficiency and the statistical evaluation of the individual surgeon’s learning 
curve have been of interest in multiple specialties, including orthopedic surgery, 
neurosurgery, otorhinolaryngology, and cardiovascular surgery, typically by utiliz-
ing quantifiable precision outcomes.1–4 The value of standardizing such outcomes, as 
measures of surgical competence to ultimately develop predictive models of surgical 
learning curves in training residents, has been addressed by authorities such as the 
Accreditation Council for Graduate Medical Education (ACGME) and the American 
Board of Ophthalmology.5 It is evident that surgeon experience improves outcomes 
and that volume of cases is one of the most important factors for establishing the 
length of the learning curve,1–4 or to determine “time to mastery”, which we defined 
as the predicted number of hours to attain .90% precision rates for first application 
of plaque placement. In ocular surgery, for instance, the number of cases required to 
achieve proficiency for phacoemulsification was found to be 75, while the number 
of scleral buckling operations found to achieve clinically stable results was 30.6,7 
  Numerous other studies have explored mastery of ocular surgical techniques, especially 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
447
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OPTH.S30307Clinical Ophthalmology 2012:6
in phacoemulsification, micro-incisional surgery, primary 
vitrectomy, glaucoma surgery, and LASIK.8–14 Other fields 
have reported learning curves for accurate placement of 
prosthetic devices,15 and the contributory role of imaging to 
evaluate optimal device placement.16–18
Tumors  treated  with  iodine-125  (I-125)  plaque 
  brachytherapy require an accurate placement typically 
including a minimum of 2 mm border around the tumor.19,20 
Techniques to facilitate accurate plaque placement include 
a modified fiberoptic light source combined with indirect 
ophthalmoscopy, and postoperative imaging studies with 
MRI or ultrasound.21–24 Currently, the most effective way to 
test for adequate plaque margins is intraoperative echogra-
phy, used in conjunction with transillumination and indirect 
ophthalmoscopy.20,24,25 Using such imaging modalities helps 
overcome the challenges in tumor localization, especially for 
posterior and juxtapapillary tumors,25 and allows the assess-
ment and location of various structures lying close to the 
tumor, such as the optic nerve.24 Intraoperative echography 
also allows for the determination of the degree of displace-
ment and the direction of displacement during adjustment. 
Furthermore, the real time nature of intraoperative diag-
nosis allows for immediate repositioning of the plaque as 
needed.25
This study tracks the reposition rates over a 19-year 
time span divided into three major periods or groups. 
Group 1 includes data published from Bascom Palmer Eye 
Institute (Miami, FL) in 1996 by Harbour et al20 which 
included 29 consecutive patients with medium-sized poste-
rior uveal melanoma undergoing I-125 plaque placement by 
a single surgeon. This study showed that 4/29 (14%) plaques 
did not cover at least one tumor margin and 2/29 (7%) were 
displaced away from the sclera due to the optic nerve or other 
structures. A total of 6/29 (21%) plaques required reposition-
ing, achieving a precise first placement position rate of 79%. 
A larger series during this time period (1992–1998), also from 
our institution, looked at choroidal tumors of medium size, 
and demonstrated similar satisfactory tumor–plaque apposi-
tion rates of 76% (n = 117).25 The current study addresses 
the learning curve (time to mastery) associated with I-125 
plaque placement in the management of uveal melanoma as 
a measurable determinant of surgical proficiency.
Methods
The study protocol was approved by the Institutional Review 
Board of the University of Miami Miller School of Medicine. 
Clinical records including operative reports were reviewed 
on 250 patients undergoing plaque placement for posterior 
uveal melanomas by one of the authors (TGM) at Bascom 
Palmer Eye Institute. Group 1 consisted of 29 consecutive 
patients starting January 1992, acquired from the study by 
Harbour et al.20 Group 2 consisted of 100 consecutive patients 
between 2002 and 2004. Group 3 consisted of 150 consecu-
tive patients between 2008 and 2009. All procedures were 
performed by one surgeon (TGM). The data recorded for each 
patient included patient demographics, tumor size, plaque 
size, date of plaque placement, plaque–tumor relationship 
as evaluated by intraoperative echography, need for plaque 
repositioning, last follow-up date, and presence of tumor 
recurrence or metastasis.
All patients presenting with posterior uveal melanoma 
underwent placement with I-125 radioactive plaque using 
standard surgical techniques.26,27 Briefly, after initial prep-
ping, draping, and anesthesia, patients underwent 360 degree 
conjunctival peritomy. All four rectus muscles were isolated 
using 2-0 Ethibond (Ethicon Inc, Somerville, NJ) suture, and 
the globe was transilluminated to mark the tumor’s location. 
If needed, one of the rectus muscles was disinserted in order 
to make room for plaque insertion. A standard Collaborative 
Ocular Melanoma Study plaque (a silastic implant includ-
ing integrated I-125 seed grooves placed into a gold-backed 
shield) with I-125 plaque seeds designed to deliver 85 Gy to 
the tumor apex, was used in all cases. After the plaque was 
brought into the field, 5-0 nylon sutures were used to secure 
the plaque. The plaque position was assessed with intraopera-
tive ultrasound by either the surgeon (TGM) or a registered 
diagnostic medical ultrasonographer using a contact B-scan 
instrument (Ophthascan S; Alcon Surgical Inc, Irvine, CA, 
or Innovative Imaging Inc, Sacramento, CA). Echographic 
studies were performed to view the tumor both longitudinally 
and transversely in order to verify plaque location relative 
to the intraocular tumor. If the plaque was found to be sub-
optimally positioned, the nylon sutures were removed and 
using ultrasound guidance, the plaque was repositioned with 
placement of new nylon sutures through the sclera to secure 
the plaque. The position was then reconfirmed using intra-
operative ultrasound. At the conclusion of the procedure, all 
plaques showed excellent positioning. If removed, the rectus 
muscle was reattached, and the conjunctiva was closed. The 
operated eye was patched and shielded with a lead shield, and 
the plaque was removed after an average of 3 days, 3 hours 
(range: 3–4 days).
Patients were examined at follow up visits every 
3–6 months and yearly by medical oncology.   Ophthalmology 
visits included a complete ophthalmic examination, 
echography, wide-field imaging and currently, spectral 
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domain optical coherence tomography (SD-OCT). Tumor 
growth greater than 0.3 mm verified either echographically or 
clinically was considered indicative of tumor recurrence.
Results
Group 1 (January 1992) revealed a plaque suboptimal 
position rate of 21% (n = 29). This percentage declined to 
12% (n = 100) from January 2002 to January 2004 (Group 2), 
and further declined to 4% (n = 150) from June 2008 to 
August 2009 (Group 3), (Figure 1).
Group 2 analysis in Table 1 shows that of plaques that 
were placed suboptimally, 25% (3/12) of plaques were 
displaced superiorly, 17% (2/12) were displaced inferiorly, 
8% (1/12) anteriorly, 8% (1/12) nasally, 8% (1/12) postero-
inferiorly, and 33% (4/12) were decentered in an unspecified 
direction. Eighty-three percent (10/12) of tumors were of 
medium size (thickness 2.5–10 mm) and 17% (2/12) were 
large (thickness . 10 mm). Mean plaque size for Group 2 
was 18.8 mm (range: 14–22 mm). In terms of tumor location, 
33% (4/12) of tumors were macularly located, 8% (1/12) 
exclusively involved the ciliary body, 25% (3/12) involved 
both the ciliary body and the choroid, and 8% (1/12) were 
juxtapapillary. Average follow-up time after plaque place-
ment was 53 months (range: 4–101 months) of which no 
patients were shown to have tumor recurrence or metastasis 
to other organs.
Group 3 (Table 2) tumor sizes were medium in 50% 
of cases and large in the other 50%. Ultrasound revealed 
that 50% (2/4) of plaques were originally decentered, 25% 
were displaced superiorly (1/4), and the other 25% (1/4) 
were displaced inferiorly. Twenty-five percent of tumors 
in Group 3 were macularly located, and 25% of cases were 
characterized as diffuse. Mean follow-up time for patients in 
Group 3 was 21.3 months (range: 20 days–36.6 months). For 
all Group 2 and Group 3 patients, time required for reposi-
tioning and evaluation ranged from 3 minutes to 15 minutes. 
At last follow up visit, none of the patients undergoing plaque 
repositioning displayed metastasis. All patients tolerated the 
procedure well without any complication.
From 1992 to 1995, precision rates of plaque placement 
were 79% (n = 29). After a mean time of 9.5 years, the precision 
rate increased to 88% (n = 100) which further increased to 
96% (n = 150) after a mean time of 15.5 years. The positive 
trend of precision rates was found to be statistically significant 
(P = 0.0007) via Chi-squared analysis. Figure 2 summarizes 
the positive correlation between precision rates and cumulative 
surgical volume. Trend analysis for this 18-year period shows 
21%
12%
Jan ‘92−Jan ’95 Jan ‘02−Jan ’04
Reposition rates
Jun ‘08−Aug ’09
4%
Figure 1 Reposition rates from 1992–1999.
Notes: Graph shows the declining trend (P = 0.007) of suboptimal plaque placement 
from January 1992 to August 2009 (17.6 years) performed by the same surgeon. 
Rates correlate to consecutive patients undergoing plaque placement for posterior 
uveal melanoma from January 1992 to January 1995 (n = 29), January 2002 to January 
2004 (n = 100), and June 2008 to August 2009 (n = 150).
Table 1 Group 2 patient characteristics – plaque reposition (12/100)
Patient Age Gender Size Location Eye Plaque displacement
1 42 M Medium Ciliochoridal OD Nasal
2 76 F Medium Ciliochoridal OS Superior
3 78 M Medium Macular w/basal extension OD Superior
4 92 F Medium Choroid OS Decentered
5 80 M Medium Choroid OD Posterio-inferior
6 92 F Large Ciliochoridal OS Decentered
7 83 M Medium Choroidal (amelanotic) OD Anterior
8 51 M Medium Macula OS Decentered
9 60 F Large Ciliary body OD Superior
10 72 F Medium Juxtapapillary OD Decentered
11 57 M Medium Macula OD Inferior
12 39 F Medium Macula with juxtapapillary component OD Inferior
Mean = 68
Notes: Twelve patients required plaque repositioning from January 2002 to January 2004 (Group 2). Eighty-five percent of these tumors were medium-sized. On primary 
placement of plaque, ultrasound showed that 4/12 plaques were decentered, 3/12 plaques were displaced superiorly, 2/12 were displaced inferiorly, 1/12 anteriorly, 
1/12 nasally, and 1/12 postero-inferiorly. Tumor sizes ranged from medium (10/12) to large (2/12). Mean plaque size was 18.8 mm (range: 14–20 mm). Average follow-up 
time after plaque placement was 53 months (range: 4–101 months) of which no patients were shown to have tumor recurrence or metastasis. Medium tumors 2.5–10 mm 
thickness; large tumors .10 mm thickness.
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Table 2 Group 3 patient characteristics – plaque reposition (4/150)
Patient Age Gender Size Location Eye Plaque displacement
1 60 M Large Diffuse OS Decentered
2 42 F Medium Macula OS Inferior
3 54 M Large Not specified OD Decentered
4 66 M Medium Not specified OS Superior
Mean = 55.5
Notes: Data from four patients that required plaque repositioning from June 2008 to August 2009 (Group 3). Tumor sizes were medium in 50% of cases and large in the 
other 50%. On primary placement of plaque, ultrasound showed that 2/4 plaques were suboptimally positioned, 1/4 plaques were displaced inferiorly, and 1/4 plaques were 
displaced superiorly. Mean plaque size was 19.75 mm (range: 16–22 mm). Average follow-up time after plaque placement was 21.25 months (range: 1–36 months) of which 
no patients were shown to have tumor recurrence or metastasis. Medium tumors: 2.5–10 mm thickness; large tumors .10 mm thickness.
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Figure 2 Cumulative number of plaque cases and precision trend. 
Notes: Graph shows the trend in the cumulative number of cases involving plaque placement over a 19-year period. Mean number of cases in study window was 85 cases/year. 
The linear trend is matched with the precision percentage in initial plaque placement, indicating that plaque precision rates increase as surgical volume increases.
that .90% precision was achieved at approximately 1275 
episcleral plaque surgical procedures.
Discussion
Precise plaque localization is critical to ensure that a   malignant 
melanoma receives optimal radioactive dosage, which 
is calculated on the assumption of precise plaque–tumor 
alignment.28 Correct plaque positioning ensures appropriate 
radiation delivery and improved local tumor control. The 
importance of local tumor control has been highlighted by 
findings that the risk of metastasis is higher for tumors that 
fail local treatment. Karlsson et al29 showed that the risk of 
metastasis at 5 years following local tumor recurrence was 
42% versus 18% without failure.29,30 In the current study, we 
show that there is a significant learning curve to the surgical 
placement of plaques in the treatment of choroidal melanoma. 
With the higher risk of metastasis with failure of local tumor 
control, this learning curve should not be underestimated.
Over the course of two decades, apposition rates increased 
21.5%; over 1200 cases were performed to achieve a .90% 
plaque precision rate. Given that the mean time for plaque 
procedure is 30 minutes, 1275 procedures corresponds to 
time to mastery with .90% precision at 637.5 hours. Hence, 
acquiring surgical techniques for optimal plaque placement 
can be challenging. Overall, this evolution in the learning 
curve illustrates the challenges of mastering precise place-
ment of radioactive plaques for posterior uveal melanoma. It 
also suggests that the addition of ultrasonography for plaque 
placement verification is a critical and beneficial tool.24
The majority of the tumors in this study with suboptimal 
plaque positions were posteriorly located. In addition to 
tumor location, ocular structures such as the optic nerve, 
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inferior oblique muscle, and posterior ciliary vessels and 
nerves can provide a challenge for plaque placement20,24,25,31 
and may even lead to subsequent plaque tilting.32 Overall, 
intraoperative ultrasonagraphy at plaque insertion will help 
verify both tumor location and plaque placement.32 Factors 
not affecting the apposition rates in our study include patient 
age, gender, and eye undergoing surgery. Juxtapapillary 
tumors also present a challenge in treatment, with notched 
plaques aiding in appropriate plaque placement. Future stud-
ies on apposition rates of notched plaques are warranted.
Limitations of this study include a small sample size and 
single surgeon, however the values between the three groups 
were found to be statistically significant (P = 0.0007).
In conclusion, the current study emphasizes significant 
learning curve associated with episcleral plaque radiotherapy 
treatment. With an increased risk of metastasis following 
failure of local tumor control, use of intraoperative ultrasound 
should be encouraged to ensure adequate plaque placement.
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